Silo Pharma, Inc. 8-K

What Happened Silo Pharma, Inc. announced it will effect a 1-for-15 reverse split of its issued and outstanding common stock, effective 4:01 p.m. Eastern Time on June 2, 2026. After the split, trading on The Nasdaq Capital Market will commence on a post-split basis under the same ticker, "SILO," at the opening on June 3, 2026. The company expects issued and outstanding shares to decrease from approximately 16.267 million to approximately 1.084 million.

Key Details

• Reverse split ratio: 1-for-15; fractional shares will be rounded up to the next whole share.
• New CUSIP for common stock: 82711P300.
• Authorized common stock will be proportionately reduced to 6,666,667 shares after the split.
• Equitable adjustments will be made to outstanding equity awards, warrants, and plan share counts and exercise prices per their terms.

Why It Matters A reverse stock split consolidates shares, reducing the number of outstanding shares and increasing the per-share price proportionally. For investors, the action does not change the company’s market value directly but affects share counts, the appearance of per-share pricing, and the share quantities on outstanding options and warrants (which will be adjusted). The CUSIP change and Nasdaq trading on a post-split basis are administrative details shareholders should note for trading and record-keeping.